Compare TTEK & CYTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TTEK | CYTK |
|---|---|---|
| Founded | 1966 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.2B | 7.6B |
| IPO Year | 1995 | 2004 |
| Metric | TTEK | CYTK |
|---|---|---|
| Price | $31.73 | $60.05 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 18 |
| Target Price | $44.00 | ★ $88.50 |
| AVG Volume (30 Days) | ★ 2.4M | 1.9M |
| Earning Date | 05-06-2026 | 05-05-2026 |
| Dividend Yield | ★ 0.86% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.40 | N/A |
| Revenue | ★ $2,964,148,000.00 | $13,368,000.00 |
| Revenue This Year | N/A | $8.73 |
| Revenue Next Year | $6.53 | $309.93 |
| P/E Ratio | $75.85 | ★ N/A |
| Revenue Growth | ★ 7.66 | N/A |
| 52 Week Low | $27.27 | $29.31 |
| 52 Week High | $43.14 | $70.98 |
| Indicator | TTEK | CYTK |
|---|---|---|
| Relative Strength Index (RSI) | 39.84 | 41.70 |
| Support Level | N/A | $59.13 |
| Resistance Level | $34.96 | $65.27 |
| Average True Range (ATR) | 1.23 | 2.54 |
| MACD | -0.18 | -0.08 |
| Stochastic Oscillator | 27.71 | 25.92 |
Tetra Tech Inc provides consulting and engineering services for environmental, infrastructure, resource management, energy, and international development markets. It specializes in providing water-related services for public and private clients. It designs infrastructure, facilities, and other structures with complex plans and resource management. it has two reportable segments. Its Government Services Group (GSG) segment includes activities with U.S. government clients (federal, state and local) and activities with development agencies world-wide. Commercial/International Services Group (CIG) segment, which derives maximum revenue, includes activities with U.S. commercial clients and international clients other than development agencies.
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.